secwatch.observer — SEC 8-K summary
======================================

Issuer:     Innoviva, Inc. (INVA)
CIK:        0001080014
Form:       8-K
Filed at:   2025-08-06T23:59:59+00:00
Accession:  0001104659-25-074730
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Innoviva Q2 2025 net income $63.7M; product sales up 54% YoY; zoliflodacin PDUFA Dec 15
--------------------------------------------------------------------------------

- Q2 2025 net income $63.7M ($1.01 basic EPS) vs net loss of $34.7M in Q2 2024.
- GSK royalty revenue $67.3M, flat YoY; IST U.S. net product sales $29.0M (+54% YoY).
- ZEVTERA (ceftobiprole) commercially launched in U.S. July 2025 for three indications.
- Zoliflodacin NDA accepted with Priority Review; PDUFA target date Dec 15, 2025; no AdCom planned.
- Cash & equivalents $397.5M; strategic healthcare asset portfolio valued at $449.3M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1080014/000110465925074730/0001104659-25-074730-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1080014/000110465925074730/tm2522376d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-074730

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer